Optimal Timing and Site Selection for Minimally Invasive Surgery in Intracerebral Hemorrhage

Overview

The MIND randomized clinical trial demonstrated excellent technical success in minimally invasive surgery (MIS) for intracerebral hemorrhage (ICH) but did not show overall mortality or disability benefit at 180 days. Analysis suggests that earlier surgical intervention and hematoma location may influence outcomes, highlighting the need for further stratified analyses.

Background

Minimally invasive surgery (MIS) is an emerging approach for treating supratentorial intracerebral hemorrhage (ICH). Prior studies, such as the ENRICH trial, have indicated that early evacuation within 24 hours, particularly for lobar hemorrhages, may improve functional outcomes. However, deep ICH presents technical challenges and may respond differently to MIS. The MIND trial contributes important data but raises questions about optimal timing and patient selection.

Data Highlights

Key Findings

• The MIND trial achieved high technical success with most patients having residual clot volumes ≤15 mL.
• Overall, the trial did not demonstrate mortality or disability benefit at 180 days post-surgery.
• Surgical timing was relatively late, with a median of nearly 28 hours from onset to evacuation.
• Less than 40% of patients underwent MIS within 24 hours, a time window previously associated with better outcomes.
• Most patients had deep hemorrhages, which may be less responsive to MIS compared to lobar hemorrhages.
• Further stratified analyses by timing, hematoma location, and surgical success could clarify subgroups that benefit most from MIS.

Clinical Implications

Clinicians should consider the timing of MIS for ICH, as earlier intervention within 24 hours may improve functional outcomes, especially in lobar hemorrhages. Patient selection based on hematoma location and achieving near-complete clot evacuation are important factors to optimize benefits. Future clinical practice and trial designs should incorporate these variables to better identify candidates for MIS.

Conclusion

The MIND trial advances understanding of MIS in ICH but underscores the importance of early surgery and hematoma location in determining patient outcomes. Additional analyses are needed to refine patient selection and optimize surgical timing.

References

1. Arthur et al. 2023 -- MIND Randomized Clinical Trial on MIS for ICH
2. ENRICH Trial -- Early Minimally Invasive Removal of Intracerebral Hemorrhage
3. Kellner et al. -- Observational Data on Onset-to-Evacuation Time and Outcomes
4. INTERACT3 Trial -- Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage